The SAGE meeting of 17-19 October 2017 was held in the Executive Board (EB) room at WHO HQ in Geneva. Available on this site you will find meeting information, background reading materials and presentations made at the meeting. The conclusions and recommendations of SAGE meeting are published in the WHO Weekly Epidemiological Record in English and French within two months of each SAGE meeting.
Related
SAGE Yellow Book for October 2017
SAGE tracking record of recommendations and action points
Technical Advisory Group on Vaccine-preventable Diseases (TAG), XXIV Meeting, Panama City, Panama, 12-14 July 2017
Global report including key updates and challenges from regions - J.M. Okwo-Bele
Meeting of the Global Advisory Committee on Vaccine Safety (GACVS), 7-8 June 2017
IVIR-AC: No background documents
Global Advisory Committee on Vaccine Safety (GACVS) - R. Pless
Product Development for Vaccines Advisory Committee (PDVAC) - D. Kaslow
Immunization and Vaccines related Implementation Research Advisory Committee (IVIR-AC) - P. Beutels
Background Paper to SAGE on Typhoid Vaccine Policy Recommendations
Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings, Vaccine publication, June 2017
Typhoid Vaccine Acceleration Consortium (TyVAC) – Executive Summary
Summary of Findings: Typhoid Vi-polysaccharide vaccine versus placebo or control vaccine in children and adults
Summary of Findings: Typhoid Ty21a vaccine versus placebo or control vaccine in children and adults
Typhoid vaccines: Evidence to recommendation Table
Introduction - I. Jani
Overview of the epidemiology and global disease burden of typhoid fever - J. Crump
Conclusions and proposed recommendations of the SAGE Working Group on Typhoid Vaccines - I. Jani
Fourteenth Meeting of the SAGE Polio Working Group (WG) WHO, Geneva, February 9-10, 2017
Cessation Risk Assessment Meeting, June 13-14, 2017: Summary
Draft Post-Certification Strategic Plan
Ousmane DM et al. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016- Worldwide, 2016–2017, Morbidity and Mortality Weekly Report 2017
Hampton LM et al. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine-Worldwide, 2016, Morbidity and Mortality Weekly Report 2016
Okayasu H et al. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization, The Journal of Infectious Diseases 2017
Polio Endgame & Legacy-Implementation, Best Practices, and Lessons Learned, The Journal of Infectious Diseases 2017
Overview of Global Polio Eradication Initiative - M. Zaffran
Post certification strategy (PCS) - B. Burkholder
Report from SAGE Polio Working Group on Polio - Y. AL-Mazrou
Tools for CSO engagement and reporting in support of national immunization plans
Global Vaccine Action Plan. Draft Secretariat Annual Report 2017
Global Vaccine Action Plan. Priority Country reports on progress towards GVAP-RVAP goals. Annex to the GVAP Secretariat Annual Report 2017
National Immunization Coverage Scorecards Estimates for 2016
Presentation of the proposed process to develop a Global Immunization Strategy 2021-2030 - C. Mantel
No background documents provided
Developing Country Vaccine Manufacturers Network (DCVMN) - S. Prasad
International Federation of Pharmaceutical Manufacturers and Associations - L. Bigger
Background paper: Proposed Revision of the Policy on Rabies Vaccines and Rabies Immunoglobolins
Appendix III: Evidence to recommendation tables for PICO questions
Overview of the global rabies situation - B. Abela-Ridder
Conclusions and proposed recommendations (Question 1,2,3,4) - K. O'Brien
Conclusions and proposed recommendations (Question 5,6,7,8,9) - K. O'Brien
Conclusions and proposed recommendations (Questions 10,11,12,13,14) - K. O'Brien
Executive Summary: SAGE October 2017, Pneumococcal Conjugate Vaccine Session
Evidence to Recommendation Tables: PCV
Current status of PCV usage and current recommendations - K. O'Brien
Review of PRIME systematic review - M. Knoll
Critical immunity thresholds paper
Measles in infants less than 6 months and effectiveness and safety of vaccination
Should an additional dose of MCV be recommended for HIV infected adolescents and adults
Measles vaccines: WHO position paper - April 2017
Rubella vaccines: WHO position paper - July 2011
Epidemiology of measles in infants younger than 6 months: analysis of surveillance data 2011-2016
Critical immunity threshold for measles elimination - S. Funk
BCG Evidence to Recommendation Tables 1-5
Mangtani et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical Infectious Diseases, 15 February 2014
Efficacy, effectiveness and duration of protection of BCG vaccination against TB - P. Mangtani
Safety of BCG vaccination and implications for HIV-exposed and infected children - K. Johansen